Eris Lifesciences Q2 Profit Soars on Domestic Growth

Eris Lifesciences announced a substantial 39.16% increase in its consolidated net profit for the September quarter, achieving ₹187.14 crore. This marks a significant improvement from the ₹134.47 crore profit recorded in the same period last year.

The company's total revenue from operations for the second quarter reached ₹892.37 crore, an increase from ₹792.41 crore in the corresponding period of the previous fiscal year. Total expenses for the quarter were ₹702.86 crore.

Driving this impressive performance was the domestic branded formulations business, which achieved 14% revenue growth. Key therapies within this segment, particularly diabetes, demonstrated strong market outperformance, with 18.5% growth driven by recent insulin and semaglutide launches.

Furthermore, Eris Lifesciences revealed that its internally developed recombinant Semaglutide has secured approval for conducting both Phase 1 and Phase 3 clinical trials, indicating a promising pipeline for future treatments.